Relay therapeutics drug shows promise in early trial
Relay therapeutics drug shows promise in early trial"
- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
A daily dose of Relay Therapeutics’ experimental drug for cholangiocarcinoma, a rare cancer of the bile ducts, led to tumor shrinkage of a third or more in 15 of 17 patients with metastatic
disease, the company said Wednesday. The results were released in an abstract at the annual meeting of the European Society of Molecular Oncology, where they will be presented in full on
Sunday. Relay’s drug, known as RLY-4008, works only in tumors that have a particular kind of mutation related to a gene for a protein called FGFR2. Other drugs exist for treating
cholangiocarcinoma patients with this mutation, but doctors believe their efficacy is limited by toxicities, including high levels of phosphorus, that prevent researchers from giving them in
high enough doses. STAT+ Exclusive Story Already have an account? Log in THIS ARTICLE IS EXCLUSIVE TO STAT+ SUBSCRIBERS UNLOCK THIS ARTICLE — PLUS DAILY COVERAGE AND ANALYSIS OF THE BIOTECH
SECTOR — BY SUBSCRIBING TO STAT+. Already have an account? Log in Individual plans Group plans View All Plans To read the rest of this story subscribe to STAT+. Subscribe
Trending News
Nr narayana murthy’s favourite books that shaped his thinkingTHE STORY OF CIVILIZATION (11 VOLUMES) BY WILL AND ARIEL DURANT This voluminous masterpiece is a must for every serious ...
Ahluwalia Contracts builds its way to the top with strong order book and rising profitsTHE LEELA PALACE in Delhi, All India Institute of Medical Sciences’ campuses in West Bengal and Maharashtra, and the air...
NITI Aayog CEO: 17 states ready with 'Viksit Bharat 2047' vision; 3rd largest economy possible in 2-3 yearsNITI Aayog CEO BVR Subrahmanyam today affirmed India's take-off stage for rapid growth, noting that with many basic serv...
Anil Ambani’s Reliance Power jumps 19% after Bhutan solar deal; but here’s why analysts warn retail investors to stay awayThis comes days after Reliance Power entered into a strategic collaboration with Druk Holding and Investments Ltd (DHI),...
Schloss Bangalore IPO: Brookfield-backed Leela Hotels raises ₹1,575 cr from anchor investorsAhead of opening of the IPO next week, Schloss Bangalore Ltd, which owns luxury hospitality brand 'The Leela' Palaces, H...
Latests News
Relay therapeutics drug shows promise in early trialA daily dose of Relay Therapeutics’ experimental drug for cholangiocarcinoma, a rare cancer of the bile ducts, led to tu...
Oscars 2016: 'hollywood is racist' host chris rock 'thought real hard'The comedian, who welcomed the audience in the Dolby Theatre to the "white People's Choice Awards", said:...
[withdrawn] civil service people survey privacy noticeGuidance CIVIL SERVICE PEOPLE SURVEY PRIVACY NOTICE This notice sets out how Cabinet Office and ORC International will u...
Touching 9/11 tributes made over the years by survivors and those who've lost loved onesNykiah Morgan holds up a photo of her mother Dororthy Morgan, who died in the 9/11 attack on the the World Trade Center....
AdweekEditor’s Picks THE ADWEEK RESOURCE LIBRARY Be a better marketer and get access to the latest Adweek-created guides, excl...